@Prof_Nick_James agree that comparison to ENZARAD and ATLAS very useful - however challenging because of slightly different entry criteria and endpoints. PROTEUS had specific demands for high numbers of involved cores. cT staging not easy to compare because of differences in use of DRE vs imaging
@DrSpratticus@ChapinMD In the NED at 4yrs data there is a lot of censoring we need to understand better. The BCR rates look better.
MFS on conventional imaging is not negative but premature, given the low number of events.
To cure a larger fraction of patients with high risk disease we will need a truly integrated approach. I am surpised that there was not more salvage RT in PROTEUS.
Perioperative Apalutamide in High-Risk Localized Prostate Cancer | New England Journal of Medicine https://t.co/rYijKEbAMH
Honored to be involved - lots to discuss and lots to come
It adds data to the discussion. The RP only substudy comes next year.
SPCG15 will be very important.
Primary PET staging not available in PROTEUS.
Comparison to ENZARAD and ATLAS will be interesting…
I am very happy that PROTEUS is positive.
@DrSpratticus@TylerSbrt The assumptions were complicated because of the dual primary endpoint (at least for a Urologist…) Will be shown on Sunday. Furthermore PSMA onboarded during the trial. Many important clinical endpoints and many discussions to come.
New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study
https://t.co/oA3mci76XD
In an international registry study of 11,154 patients, investigators developed PPP3 nomograms integrating clinical features and PSMA-PET PROMISE metrics to predict 3-, 5-, and 7-year overall survival in #ProstateCancer
Developed and validated across 35 global sites,
✅ Models demonstrated strong discrimination (C-index ~0.83–0.84).
✅PPP3 performed as well as or better than existing clinical risk scores, supporting PSMA-PET–based risk stratification for guidelines, clinical decision-making, and trial design.
@CalaisJeremie@DrMHofman@thomashopemd@drlouiseemmett@DrAGafita@ProfKHerrmann@ProfHadaschik@Dr_K_Rahbar@bjartell@OncoAlert 🚨
@silkegillessen@AOmlin@weoncologists
#EAU26
PEACE-1 RT is now published online at @TheLancet
Some differences with STAMPEDE
Key messages: RT to prostate in M1 #prostatecancer
1. improves rPFS but not OS in low volume
2. improves CRPC-FS & reduces serious GU SAE irrespective of volume
Full text: https://t.co/bfPzTdWTro
Happy to share: Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker: Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate Cancer - ScienceDirect https://t.co/rbpdSScJHY
We are very proud that the paper is online! Sincere thanks to our scientific committee and all panellists. Manuscript is open access, please use and distribute it! Hope to see you at the first edition of @APCCC_Lugano Diagnostics @ProfKHerrmann@stefanofanti4
Delighted to share our latest on #18F_PSMA_PET just published in cool new @JUOpenPlus!
•n=1335 scans from 1220 men
•1°: PSMA 96% vs MRI 89% sens. for pros lesions at RP
•2°: PSA 0.2-0.49 post RP/RT ➡️ avidity in 57.8%
BUT high false +ves (esp ribs)
https://t.co/xlZzcsApIo
Sharing key takeaways from my #ASTRO2024 presentation! I'm grateful for the support I've received—thank you, @ASTRO, @MGHCancerCenter @theNCI & @Pcfnews. It’s a win for our field that both #ProtonTherapy & #IMRT are equally highly effective for localized #ProstateCancer.
🚀Big News! Excited to share our work “The Interplay of Mutagenesis and ecDNA Shapes Urothelial Cancer Evolution” published in @Nature! https://t.co/sU6uF9rNvI
Our latest paper on risk stratified prostate cancer testing - TARGET study, a simultaneous evaluation of PRS, PSAd, F/T PSA, phi in a PSA triggered MRI diagnostic pathway + testing different defn of ‘clinical significance’ https://t.co/6yZGFFZ5RQ
In patients with muscle-invasive bladder cancer, extended lymphadenectomy did not improve disease-free or overall survival as compared with the standard procedure and was associated with higher morbidity and mortality. Full SWOG S1011 trial results: https://t.co/mYGY3Zd2MX